Skip to main content
Industry Update
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15
- Alejandra Castanon,
- Benjamin D Bray, and
- Sreeram V Ramagopalan
e240033
Published Online:28 March 2024
Letter to the Editor
Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema
- Max Schlueter and
- Sandra Nestler-Parr
e230165
Published Online:28 March 2024
Letter in Reply
Letter in reply: network meta-analysis for indirect comparison of lanadelumab and for the treatment of hereditary angioedema
- Maureen Watt,
- Mia Malmenas, and
- Katrin Haeussler
e240041
Published Online:12 April 2024
Research Article
Gastrointestinal adverse effects associated with the use of intravenous oliceridine compared with intravenous hydromorphone or fentanyl in acute pain management utilizing adjusted indirect treatment comparison methods
- Joseph Biskupiak,
- Gary Oderda,
- Diana Brixner, and
- Todd L Wandstrat
e230041
Published Online:18 March 2024
Assessing the performance of physician's prescribing preference as an instrumental variable in comparative effectiveness research with moderate and small sample sizes: a simulation study
- Lisong Zhang,
- Jim Lewsey, and
- David A McAllister
e230044
Published Online:3 April 2024
Comparing the performance of two-stage residual inclusion methods when using physician's prescribing preference as an instrumental variable: unmeasured confounding and noncollapsibility
- Lisong Zhang and
- Jim Lewsey
e230085
Published Online:3 April 2024
Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer
- Alessandria Struebing,
- Chelsea McKibbon,
- Haoyao Ruan,
- Emma Mackay,
- Natalie Dennis,
- Russanthy Velummailum,
- Philip He,
- Yoko Tanaka,
- Yan Xiong,
- Aaron Springford, and
- Mats Rosenlund
e230175
Published Online:4 April 2024
Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
- Clara Lam,
- Brandon Diessner,
- Katherine Andrade,
- Sydnie Stackland,
- Leah Park,
- Sandhya Mehta,
- Feng Lin, and
- Winghan Jackie Kwong
e230166
Published Online:22 April 2024
Review
The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health
- Chakrapani Balijepalli,
- Lakshmi Gullapalli,
- Juhi Joshy, and
- Nigel SB Rawson
e230178
Published Online:3 April 2024